Search results
Jul 14, 2020 · Takahiro Fukuda & Takahiro Fukuda. Research Institute for Radiation Biology and Medicine, Department of Hematology and Oncology, Hiroshima University, Hiroshima, Japan. Tatsuo Ichinohe
- Hiroyuki Muranushi, Takero Shindo, Masakatsu Hishizawa, Masahito Tokunaga, Atsushi Wake, Nobuaki Nak...
- 2021
Takahiro Fukuda's 684 research works with 7,701 citations and 1,958 reads, including: Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical...
Mar 25, 2023 · Takahiro Fukuda, Yoshiko Atsuta & Makoto Yoshimitsu. Bone Marrow Transplantation 58 , 729–731 ( 2023) Cite this article. 278 Accesses. 1 Citations. 2 Altmetric. Metrics. To the Editor: Adult...
Jan 29, 2021 · Takahiro Fukuda. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan. Yoshiko Atsuta
- Masatoshi Sakurai, Takehiko Mori, Koji Kato, Minoru Kanaya, Minoru Kanaya, Shohei Mizuno, Souichi Sh...
- 2021
Oct 10, 2021 · Correspondence: Takahiro Fukuda, Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; e-mail: pj.og.ccn@adukufat.
- 10.1182/bloodadvances.2021004932
- 2021/10/10
- Blood Adv. 2021 Oct 26; 5(20): 4156-4166.
Takahiro FUKUDA | Cited by 1,432 | of Toyo University, Bunkyō-ku | Read 57 publications | Contact Takahiro FUKUDA
Oct 1, 2016 · Pretransplantation Mog was significantly associated with an increased risk of GVHD-related mortality, which supports the relevance of CCR4-expressing Tregs after allo-HSCT in humans. In clinical practice, Mog should be cautiously used for patients with ATLL who are eligible for allo-HSCT.
